{
  "docId": "019de075-746f-7643-8ae7-19646171e75b",
  "docSlug": "e49fd8f0d5e7ac656caa3720c9a74f92",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 28 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 28,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide outlines two parallel study arms with randomization at week 24.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-746f-7643-8ae7-19646171e75b/18",
  "deckHref": "/decks/019de075-746f-7643-8ae7-19646171e75b",
  "deckJsonHref": "/decks/019de075-746f-7643-8ae7-19646171e75b.json",
  "deckAnchorHref": "/decks/019de075-746f-7643-8ae7-19646171e75b#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.65,
        "x": 0.3,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Clinical trial timeline showing two arms with randomization at week 24 and follow-up periods.",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec9705ec-9cc1-4e1d-9199-cfe56e33de3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "POC Phase 2a clinical trial evaluating imdusiran in combination with Vaccitech's immunotherapeutic, VTP-300, with or without low dose nivolumab, and a NA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c756b7c-8101-4b80-aac3-9d8dc48cc33d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Primary objective: evaluate safety and reactogenicity of imdusiran followed by VTP-300 or placebo. At week 48 all participants who are eligible to discontinue NA therapy will be followed for 48-weeks. Expanded the clinical trial to include an additional arm with nivolumab (Opdivo), and dosed first patient in this arm in the first half of 2023. Full rights retained by the Companies of their respective product candidates and all costs split equally",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e76a3876-4ecc-4dc6-91a2-7468de5c9d81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "title",
      "text": "AB-729-202: Phase 2a POC Clinical Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29042d78-9dda-44ce-8e57-4768bbc86883",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "4b6db566-6a42-4f1c-a30d-a8d747cf99d4",
      "evidence": "Visual representation of clinical trial phases over weeks.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}